Valdecoxib for treatment of primary dysmenorrhea-Reference-Cited by-同舟云学术

Valdecoxib for treatment of primary dysmenorrhea

Published:2005-01 Issue:1 Volume:20 Page:62-67
ISSN:0884-8734
Container-title:Journal of General Internal Medicine
language:en
Short-container-title:J Gen Intern Med

Author:

Daniels Stephen E.,Torri Sarah,Desjardins Paul J.

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

http://www.springerlink.com/index/pdf/10.1111/j.1525-1497.2004.30052.x

Reference26 articles.

1. Dawood MY. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med. 1988;84(suppl 5A):23–9.

2. Rosenwaks Z, Seegar-Jones G. Menstrual pain: its origin and pathogenesis. J Reprod Med. 1980;25(4 suppl):207–12.

3. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonuclerogenic. Proc Natl Acad Sci USA. 1994;91:3228–32.

4. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. 1994;343:769–72. Erratum in Lancet. 1994;343:1048.

5. Copeland RA, Williams JM, Giannaras J, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA. 1994;91:11202–6.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical trials and future perspectives of antiinflammatory agents;Recent Developments in Anti-Inflammatory Therapy;2023

2. Valdecoxib Protects against Cell Apoptosis Induced by Endoplasmic Reticulum Stress via the Inhibition of PERK-ATF4-CHOP Pathway in Experimental Glaucoma;International Journal of Molecular Sciences;2022-10-26

3. Valdecoxib attenuates lipid-induced hepatic steatosis through autophagy-mediated suppression of endoplasmic reticulum stress;Biochemical Pharmacology;2022-05

4. Natural products: a rising star for treating primary dysmenorrhea?;Traditional Medicine Research;2022

5. Primary and secondary dysmenorrhea, premenstrual syndrome, and premenstrual dysphoric disorder;Comprehensive Gynecology;2022